Oral Solid Dosage Pharmaceutical Formulations Market

By Drug Release Mechanism;

Immediate Release and Extended Release - Sustained Release and Controlled Release, and Others

By Product Type;

Tablets, Capsules, Powders, Granules, Lozenges, and Others

By Application;

Cardiovascular, Anti-infectives, Central Nervous System, Pain Management, Anti-inflammatory, and Others

By Distribution Channel;

Hospital Pharmacy, Retail Pharmacy, Drug Stores, and Online Pharmacy

By Geography;

North America, Europe, Asia Pacific, Middle East & Africaz, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn268761363 Published Date: August, 2025

Oral Solid Dosage Pharmaceutical Formulation Market Overview

Oral Solid Dosage Pharmaceutical Formulation Market (USD Million)

Oral Solid Dosage Pharmaceutical Formulation Market was valued at USD 76,675.38 million in the year 2024. The size of this market is expected to increase to USD 119,152.51 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 6.5%.


Oral Solid Dosage Pharmaceutical Formulations Market

*Market size in USD million

CAGR 6.5 %


Study Period2025 - 2031
Base Year2024
CAGR (%)6.5 %
Market Size (2024)USD 76,675.38 Million
Market Size (2031)USD 119,152.51 Million
Market ConcentrationMedium
Report Pages371
76,675.38
2024
119,152.51
2031

Major Players

  • Pfizer Inc.
  • Novartis AG
  • Johnson & Johnson
  • GlaxoSmithKline plc
  • Sanofi S.A.
  • Merck & Co., Inc.
  • AstraZeneca PLC
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Oral Solid Dosage Pharmaceutical Formulations Market

Fragmented - Highly competitive market without dominant players


The Oral Solid Dosage Pharmaceutical Formulation Market remains a cornerstone of modern drug delivery due to the high preference for tablets and capsules. Accounting for over 60% of global pharmaceutical consumption, OSD forms continue to lead because of their convenience, patient adherence, and economical production. Their versatility makes them ideal for a wide range of therapeutic applications.

Innovation in Drug Delivery Systems
Technological innovation is reshaping the market, with more than 45% of new developments focused on enhancing drug solubility, stability, and bioavailability. Controlled and delayed-release formulations are gaining traction for delivering long-term therapeutic effects with fewer doses. These innovations are improving patient compliance and setting new benchmarks for treatment efficacy.

Automation and Quality-Focused Manufacturing
The shift toward automation and quality-driven production has redefined OSD manufacturing standards. Over 35% of companies are adopting QbD practices and digitized workflows to ensure product uniformity and faster scale-up. This evolution supports regulatory compliance and allows for seamless production of complex formulations with minimal variability.

Expansion of the Generic Drug Segment
With nearly 70% of all OSD prescriptions being generics, the market is strongly driven by cost-saving initiatives and patent expirations. The rise in generic formulations enables greater accessibility to essential medications. This trend continues to stimulate innovation while reducing development timelines and costs for pharmaceutical firms.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Drug Release Mechanism
    2. Market Snapshot, By Product Type
    3. Market Snapshot, By Application
    4. Market Snapshot, By Distribution Channel
    5. Market Snapshot, By Region
  4. Oral Solid Dosage Pharmaceutical Formulation Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Innovation in formulation
        2. Increasing chronic diseases
        3. Patient preference
        4. Regulatory support
      2. Restraints
        1. Patent expirations
        2. Pricing pressures
        3. Regulatory hurdles
        4. Counterfeit drugs
      3. Oppourtunities
        1. Biologics conversion
        2. Personalized medicine
        3. Digital health integration
        4. Market expansion in Asia
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Oral Solid Dosage Pharmaceutical Formulation Market, By Drug Release Mechanism, 2021 - 2031 (USD Million)
      1. Immediate Release
      2. Extended Release
        1. Sustained Release
        2. Controlled Release
      3. Others.
    2. Oral Solid Dosage Pharmaceutical Formulation Market, By Product Type, 2021 - 2031 (USD Million)
      1. Tablets
      2. Capsules
      3. Powders
      4. Granules
      5. Lozenges
      6. Others
    3. Oral Solid Dosage Pharmaceutical Formulation Market, By Application, 2021 - 2031 (USD Million)
      1. Cardiovascular
      2. Anti-infectives
      3. Central Nervous System
      4. Pain Management
      5. Anti-inflammatory
      6. Others
    4. Oral Solid Dosage Pharmaceutical Formulation Market, By Distribution Channel, 2021 - 2031 (USD Million)
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Drug Stores
      4. Online Pharmacy
    5. Oral Solid Dosage Pharmaceutical Formulation Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Pfizer Inc.
      2. Novartis AG
      3. Johnson & Johnson
      4. GlaxoSmithKline plc
      5. Sanofi S.A.
      6. Merck & Co., Inc.
      7. AstraZeneca PLC
      8. Teva Pharmaceutical Industries Ltd.
      9. Bayer AG
  7. Analyst Views
  8. Future Outlook of the Market